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Introduction: Currently, 424 million people aged between 20-79 years worldwide are diabetic. 
More than 25% of adults aged over 65 years in North America have Type 2 diabetes mellitus 
(DM). Diabetes-induced osteoporosis (DM-OS) is caused by chronic hyperglycemia, advanced 
glycated end products and oxidative stress. The incre se in the prevalence of DM-OS has 
prompted researchers to develop new biological therapies for the management of DM-OS. 
Areas covered: This review covered the current and novel biological agents used in the 
management of DM-OS. Data were retrieved from PubMed, Scopus, American Diabetes 
Association and International Osteoporosis Foundation websites, and ClinicalTrials.gov. The 
keywords for the search included: DM, osteoporosis, and management. 
Expert opinion: Several biological molecules have been examined in order to find efficient 
drugs for the treatment of DM-OS. These biological agents include anti-osteoporosis drugs: net 
anabolics (parathyroid hormone/analogues, androgens, calcilytics, anti-sclerostin antibody), net 
anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, 
bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, 
sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, 
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medications that effectively decrease hyperglycemia and, at the same time, maintain bone health 
would be an ideal drug/drug combination for the treatment of DM-OS. 
 
Key words: Diabetes-induced osteoporosis, anti-diabetic drugs, bone mineral density, bone, 
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Article highlights 
• Osteoporosis is a common, chronic metabolic disease affecting more than 200 million 
people world wide 
• Osteoporosis is 4-5 times higher in people with diabetes mellitus (DM) compared to non-
diabetic people 
• The financial burden of osteoporosis-induced fractures was $17 billion in 2005, in the 
USA. This amount is expected to double within the next 20 years. 
• Risk factors for diabetes-induced osteoporosis include genetic predisposition, age > 50 
years, a sedentary lifestyle, smoking, chronic alcohol consumption, use of medications 
such as corticosteroids and proton pump inhibitors.  
• Optimal glycemic control is key to preventing and managing diabetes-induced 
osteoporosis 
• The safest hypoglycemic drugs in diabetic patients suffering from osteoporosis include, 
metformin and GLP-1 receptor agonists. The most beneficial drugs against osteoporosis 
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Abbreviations 
 
Alpha-1 coll = alpha-1 collagen 
AGE = Advanced glycated end products 
Akt = Protein kinase B 
ALP = Alkaline phosphatase  
ATP = Adenosine triphosphate 
BMD = Bone mineral density  
DM = Diabetes mellitus 
DM-OS = Diabetes-induced osteoporosis 
DPP-4 = Dipeptidyl peptidase 4 
FDA = Food and Drug Administration 
GLP-1 = Glucagon like peptide-1 
HbA1c = Glycated hemoglobin 
IGT = Impaired glucose tolerance  
AMPK = Adenosine monophosphate-activated protein kinase  
PI3 = Phosphoinositol 3 kinase 
PPAR-γ = Peroxisome proliferator-activated receptor gamma  
PTH= Parathyroid hormone 
PTHrP = Parathyroid hormone-related protein  
RAGE = Advanced glycated end products receptor 
RANKL = Receptor activator of nuclear factor kappa-B ligand  
ROS = Reactive oxygen species 
RUNX2= Runt-related transcription factor 2  
SERM = Selective estrogen receptor modulators  
SGLT2 = Sodium glucose co-transporter 2  
T1DM = Type 1 diabetes mellitus 
T2DM = Type 2 diabetes mellitus 
TC =      Total cholesterol 
UV = Ultraviolet 
VLDL = Very low density lipoprotein 
ERK = Extracellular-signal-regulated kinases 
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1. Introduction 
 
1.1. Diabetes mellitus and osteoporosis 
 
Diabetes mellitus (DM) is a common and chronic endocrine disease prevalent in all regions of 
the globe. It is, however, more common among urban dwellers compared to those living in rural 
and suburban areas [1]. DM is characterized by hyperglycemia, polyuria, polydipsia and 
polyphagia. DM consists of two major types, type 1 (T1DM) and type 2 (T2DM). T1DM is 
caused by a selective immune destruction of pancreatic beta cells [2], leading to significant loss 
in blood insulin. The serum of patients suffering from T1DM may contain antibodies against 
pancreatic beta cells or their cellular components [1, 2]. In contrast, T2DM is common amongst 
adult and senior members of the population and accounts for about 90% of people with DM [1]. 
T2DM was previously called non-insulin-dependent DM [3], because the patient still has DM 
irrespective of the fact that the insulin level may in fact be normal or even higher. The patient 
has chronic hyperglycemia, a key sign for the diagnosis of DM. It is similar to a case of “poverty 
in the midst of plenty”. The patient has a high concentration of glucose in the blood that is not 
taken up by either, fat, muscle or liver cell, because of insulin resistance, which means that the 
action of insulin molecule is compromised. Insulin resistance may be caused by a defect in either 
the insulin or GLUT4 receptor molecule [4] or a combination of both. The postprandial increase 
in insulin seen after a meal [5] fails to bring blood glucose level down several hours afterwards, 
resulting in sustained hyperglycemia. Other types of DM include gestational diabetes (GDM), a 
variant of glucose intolerance seen in pregnant women [6]. GDM is said to be induced by 
increase in the level of several hormones seen after the onset of pregnancy. Increase in the level 
of growth hormone, human placental lactogen, progesterone, estrogen and other hormones that 
increase during pregnancy appears to grossly impair the metabolism of insulin and glucose [6], 
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condition where bone becomes porous because it has lost bone components, failed to make 
enough bone tissue or a combination of both. In fact, many reports have shown that DM is 
associated with abnormal bone formation leading to bone fragility and poor strength [7, 8]. In 
addition to DM several other factors can lead to the development of osteoporosis. These include 
low levels of estrogen and androgen; hormonal disease such as Cushing syndrome, 
hyperparathyroidism, and hyperthyroidism [9]. Genetic diseases (aromatase deficiency, 
mutations, Marfan syndrome, homocystinuria, Ehlers-Danlos syndrome) affecting the 
metabolism of type 1 collagen may also result in the development of osteoporosis [9]. Moreover, 
increasing age, alcohol intake, heavy smoking, inadequate sun exposure, diet deficient in 
calcium, small body weight may also predispose individuals to osteoporosis. Out of all of these 
parameters, ageing is a key and predominant risk factor for the development of osteoporosis [10-
15]. Body weight, obesity or cachexia influence how skeletal bone responds to remodeling [16]. 
This means that individuals with small body weight are at risk of developing osteoporosis 
compared to those with heavier body weight [17]. In addition to these risk factors, genetic 
studies showed that skeletal geometry, BMD and metabolism of bone turnover could be inherited 
[18]. The factors regulating these genetic manifestations in bone have not been clearly elucidated 
[18] but mutations of genes that regulate the metabolism of different components of bone have 
been implicated [20]. 
Drugs used in the treatment of other diseases including but not limited to hypertension, epilepsy, 
multiple myeloma, and other malignancies have the tendency to induce osteoporosis. Other 
medications like vitamins A and D, heparin may also cause osteoporosis, especially when used in 
very high doses [9]. Table 1. 
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Factor Action Reference
1. Genetic predisposition a). Skeletal geometry, BMD, bone turnover  
 are inheritable 
b). Mutation in estrogen α, β receptor gene, 
vitamin D receptor coding gene impairs BMD 
18, 19 
 
2. Age Ageing causes significant reduction in BMD 14 
3. Weight in infancy Small weight in infancy predispose to low BMD 
in later life  
9 
4. Physical inactivity and a 
sedentary lifestyle 
Sedentary lifestyle reduces BMD 11 
5. Sun exposure Inadequate sun exposure reduces BMD  14 
6. Diet Inadequate intake of dairy products reduces 
BMD   
15 
7. Smoking  Reduces BMD 12 
8. Chronic alcohol consumption Controversial 20 
9. Medications (Corticosteroids, 
PPI) 
Causes secondary osteoporosis; PPI inhibits 
calcium uptake 
13 
10. Low body weight  Body weight loss is associated with loss in BMD 17 
BMD = Bone mineral density; PPI=Proton pump inhibitors 
 
1.2. Epidemiology of diabetes mellitus and osteoporosis 
 
1.2.1. Diabetes mellitus: According to the 2017 International Diabetes Federation report, 424.9 
million people aged 20-79 years worldwide have DM. This accounts for about 8.8% of the world 
population of 4.84 billion in this age group [21]. This percentage is much higher (11.3%) in older 
age group. The number of diabetic patients is estimated to reach 626.6 million in 2045, making 
up of more than 9.9% of the total world population amongst people aged 20-79 years. The 
number of people with impaired glucose tolerance (IGT) is equally high. In 2017, 7.3% of the 
world’s population between 20-79 years of age has a form of IGT. This number is projected to 
reach 8.3% by the year 2045 [21]. In the USA for example, the prevalence of DM is put at 9.3% 
of the population with an additional 28% in the pre-diabetes stage [22]. This observation is 
particularly true for the Middle East and North Africa region and Micronesia were the prevalence 
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DM in these developing regions has been attributed to the adoption of Western diet, life style and 
reduced physical activity. Paul Zimmet referred to this phenomenon as “coca-colonization” in 
2000 [23]. All of these reports show that the health risks posed by DM including diabetes-
induced osteoporosis will continue to grow. 
 
1.2.2. Osteoporosis: When compared to DM, osteoporosis is also a common metabolic disease 
that currently affects more than 200 million people globally. It is more common in women 
compared to men and its prevalence increases as we age. For example, approximately, one out 
two women over the age of 90 years will have osteoporosis [24]. 37% of the total number of 
osteoporosis patients resides in Europe, USA and Japan [25], however, projected increase in the 
prevalence of osteoporosis have been reported in several regions of the world including Asia, 
Middle East and Africa.  In fact, it is estimated that by the year 2050, Asia will account for 50% 
of all worldwide hip fractures due to osteoporosis [26]. This is because osteoporosis is 
significantly underreported and undertreated in major Asian countries including China and India, 
where a large percentage of the population live in rural areas [27]. Improvement in healthcare 
delivery in the future will allow more people, especially those in rural areas, with osteoporosis to 
be diagnosed.   
The trajectory of the epidemiology of DM is similar to that of osteoporosis. The projected 
increase in the number of people with diabetes will most likely contribute to the increase in the 
number of patients with diabetes-induced osteoporosis. 
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Micro- and macro-angiopathy, neuropathy coupled with increased formation of advanced 
glycated end (AGE) product [28] prevent optimal blood flow and impair the overall structure and 
function of bone. Reports have shown that T1DM is associated with a reduced bone mineral 
density (BMD) that predisposes to an increased risk of bone fracture [10]. In fact, a study 
conducted in a Middle East country showed that 46% of postmenopausal women suffering from 
DM has osteoporosis [29]. 
 
It is worth noting, however, that BMD differs in T1DM compared to T2DM. In contrast to 
T2DM, T1DM is associated with a reduced BMD [30]. T1DM-induced reduction in BMD is 
partly due to early onset of diabetes, reduced formation of bone [31], probably due to poor 
development. In spite of the chronic hyperglycemia, most studies reported that patients with 
T2DM have paradoxically displayed increased BMD [30]. The increased BMD in T2DM 
patients has been attributed to the high BMI seen in these patients. High BMI is an important 
feature in patients with T2DM [32].  In spite of the high BMD in T2DM, bone fractures are 
equally common compared to T1DM because of bone fragility and micro-cracks [33] resulting 
from micro-vascular complications. 
 
 
2.1.  Mechanism of diabetes-induced osteoporosis  
 
DM is associated with chronic elevation in plasma blood glucose. Persistent high blood glucose 
induces oxidative stress and toxicity that destroys the few remaining viable pancreatic beta cells, 
leading to a further deterioration of DM [28]. Chronic hyperglycemia causes severe impairment 
in lipid, carbohydrate and protein metabolism. Disruption in lipid metabolism results in increased 
level of very low density lipoprotein (VLDL) and total cholesterol (TC) [34], resulting in the 
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accumulation of fat will result in atherosclerosis and narrowing of vascular lumen. Impaired 
vascular structure and function affect blood flow to a large variety of organs including but not 
limited to bone, retina, kidney, neurons of the central and peripheral nervous systems, many 
other vital tissues and organs such as heart [28]. Continued, and long-term deposition of VLDL 
in the sub-endothelial layer of blood vessels may lead to the development of micro- and macro-
angiopathy [28] resulting in poor blood supply to bone. Bone tissue will not be functioning 
properly if the vasculature is poor and may develop structural anomalies such as micro-cracks. 
Another factor that may also contribute to the development of diabetic complications is 
hyperglycemia-induced oxidative stress. Oxidative stress facilitates the release of reactive 
oxygen species (ROS) such as hydroxyl radicals, superoxides, peroxides, alpha- and singlet- 
oxygen [35]. It is well known that chronic hyperglycemia stimulates the formation of advanced 
glycated end products [28], which in turn cause structural changes in molecules involved in the 
formation of   type 1 collagen and other biological factors responsible for bone integrity. In fact, 
it has been shown that pentosidine, an AGE product causes non-enzymatic glycation of type 1 
collagen cross-links resulting in impaired bone mass formation [36]. Several studies have shown 
that receptors for AGE products (RAGE) prevent the proliferation of osteoblasts via inhibition of 
a variety of signaling pathways including PI3, ERK and Wnt [37]. Moreover, RAGE has been 
shown to increase the formation of osteoclasts [38] leading defective bone formation. The ability 
of AGE products to polymerize after binding to RAGE causes cross-linkages in skeletal proteins 
resulting in bone stiffness and fragility [39]. All of these AGE-induced changes may result in 
deranged biomechanical parameters of bone. DM also appears to affect total protein content of 
tissues of which collagen is a member. A marked decrease in the protein content was measured 
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studies have shown that DM caused a significant reduction in pancreatic amylase [41]. In a 
similar pattern, crucial enzymes, such as alkaline phosphatase, implicated in the formation of 
bone are reduced after the onset of DM [42]. Recent studies have shown that plasminogen 
activator inhibitor-1 (PAI-1) may play a role in the pathogenesis of osteoporosis because PAI 
deficiency reduces bone loss in experimental animals by inhibiting osteoclast activity and 
modulating alkaline phosphates function [43]. PAI-1 was significantly reduced in T2DM patients 
with osteoporosis when compared to T2DM patients without osteoporosis [44]. Osteocalcin, a 
hormone produced by osteoblast that has been reported to stimulate insulin release and 
mineralization of bone [45], may also play a role in the pathogenesis of DM-OS.  
A combination of lipid deposition, poor blood supply, glucose toxicity coupled with oxidative 
stress may lead to the development of osteoporosis.  
 
2.2. Effect of diabetes-induced osteoporosis on patients’ quality of life 
 
DM is associated with high mortality and morbidity if not treated. The reason for this is that DM 
causes multi-organ disease and complications that may severely impair vision, cardiac and 
kidney functions, and the musculoskeletal system. The addition of osteoporosis puts extra burden 
on a patient with all of the unpleasant morbidities associated with DM. Osteoporosis by itself 
puts tremendous burden on the patient. The personal and economic burden placed on diabetes-
induced osteoporotic patient, if not well managed, is far more severe that those seen in patients 
suffering from malignant disease or even bronchial asthma [46]. The chances of an osteoporosis 
patient of having another bone fracture, after a previous one is more than 86% [47]. Bone 
fracture risk is a major health issue in patients with DM-induced osteoporosis because many of 
the key hypoglycemic agents, such as insulin, sulfonylureas, sodium-glucose cotransporter-2 
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especially in elderly patients. It is thus, extremely important to select the right hypoglycemic 
drugs for this group of patients. The number of days spent in health care facilities by DM-OS 
patient has been shown to be significantly higher when compared to other chronic, non-
infectious diseases such as DM alone or cancer of the breast [48]. 
 
3. Management of patients with diabetes-induced osteoporosis 
 
Since osteoporosis is a consequence of net bone loss and/or abnormal microarchitecture due to 
the derangement in the delicate harmony between bone formation and reabsorption, most 
management regimens look at factors that would either, increase net bone formation, reduce net 
bone resorption or repair abnormal structure [49]. Medication that increases net bone formation 
[e.g. parathyroid hormone, abaloparatide (PTHrP-1-34 analogue)] will increase bone mineral 
density (BMD), while net anti-resorptive drugs (e.g. calcitonin, denosumab, oestrogen, selective 
estrogen receptor modulators, bisphosphonates, strontium ranelate) prevent degradation of 
components of bone. Other types of treatment include the administration of calcium and vitamin 
D to facilitate optimal mineralization of bone [49]. Lifestyle modification (physical activity, diet) 
is crucial to maintaining an optimal bone health. Physical activity significantly reduces the risk 
of developing osteoporosis by increasing osteogenesis and bone formation via mechano-
signaling and mechano-transduction processes [50]. Drugs and life style modifications employed 




















Information Classification: General 
Factor Action on bone health Effect on DM Reference
1. Sunshine 7-dehydrocholesterol is 
converted to vitamin D3 in the 
skin by UV light  
 See Vitamin D 51 
2. High protein diet Provides necessary amino acid 
pool for the synthesis of bone 
matrix proteins. Maintains BMD 
No specific positive 
or negative effect  
52 
3. High vegetable and fruit 
diet 
Possibly via antioxidant content 
of fruits and vegetables  
Reduces DM risk  53 





5. Vitamin D Improves bone health through 
Ca2+ mobilization 
Reduces HbA1c and 
fasting blood glucose 
55 
6. Calcium rich diet Improves bone health                No specific effect 16 
7. Minerals (e.g. K+, Mg2+) Maintain BMD via alkaline-
producing moiety 





Table 3A: Potential drugs with net anabolic properties (target cell: osteoblast) for the 
treatment of diabetes-induced osteoporosis  
 
Factor Action Effect on DM Reference
1. Parathyroid hormone 
[rhPTH(1-34, PTH(1-84)] 
      (teriparatide, abaloparatide  
and analogues 
PTH stimulate osteoblast to 
deposit osteoid and 
significantly increase BMD; 






 57, 58,  59 
60, 61 
2. Androgens Increase BMD in childhood 
osteoporosis 
Low dose inhibits 




Potential anabolic drugs:    
3. Calcilytics (e.g. NPS 
2143) 
Reduce calcium-sensing 
receptor, thereby increasing 
the pool of PTH 
See PTH 64 
4. Anti-sclerostin antibody 
(Romosozumab – 
Approved in Japan but not 
yet in USA) 
Blocks sclerostin, improves 
osteoblast function via Wnt/ β-
catenin  pathway 
None reported 65, 66 
5. Osteocalcin Stimulates osteoblast 
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Table 3B: Potential drugs that prevent net resorption of bone (target cell: Osteoclast) for 
the treatment of diabetes-induced osteoporosis  
 
Factor Action Effect on DM Reference
1. Calcitonin Reduces bone resorption Controversial 68, 69 
2. Estrogen Inhibits osteoclast 
differentiation, blocks sclerostin 









sclerostin   
Neutral 70,  





Significantly inhibits osteoclast 
activity 
Significant 
reduction in DM 
risk 
71, 72, 73, 
74 
6. RANKL antibody 
(Denosumab) 
Inhibits the formation, 









7. Cathepsin K inhibitors   Block the ability of osteoclasts 
to degrade bone matrix 
Unknown 78 




3.1.    Osteoporotic drugs with anabolic properties 
3.1.1. Parathyroid hormone (PTH) stimulates osteoblasts to deposit osteoid resulting in 
new bone formation [57]. Recombinant version of PTH (hPTH-(1-34) was approved by 
the Food and Drug Administration (FDA) in 2002 and marketed as teriparatide. It is a 
potent anabolic drug for the treatment of osteoporosis because it significantly increases 
BMD [58], and bone size. Attempts to produce and market analogues (ostabolin-C) of 
PTH did not materialize. Ostabolin-C was withdrawn by Zelos Pharmaceutical in 2009 
[59]. However, abaloparatide, a PTH protein analogue, was approved by the Food and 
Drug Administration (USA) in April 2017.  Abalopartide has antioxidant properties and 
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by 86% and 43%, respectively in older women suffering from osteoporosis [79]. What 
then is the impact of PTH on glucose homeostasis? It was reported, from a study 
involving 1,175 patients with type 2 DM, that higher levels of PTH are associated with 
lower level of fasting blood glucose and HbA1c [80]. In contrast, some reports show that 
8% of patients with primary hyperparathyroidism have DM when compared to the 
general population [81]. Recent reports showed that high concentrations of PTH are 
associated with hyperglycemia in a study of elderly pre-diabetic patients [60]. Reduced 
insulin sensitivity has also been reported in pregnant women with high PTH level [61]. 
Until more definite studies have been performed to assess the effect of PTH on diabetes, 
prescription of PTH analogs should therefore be done with care in diabetes–induced 
osteoporosis. 
 
3.1.2. Androgens such as testosterone have been suggested for the treatment of childhood 
osteoporosis [62]. However, the impact of androgens on childhood DM is unknown. In 
contrast, clinical studies performed in adult population showed that low testosterone level 
predispose patients to DM [82], while high levels of testosterone increases insulin 
sensitivity [63].   
 
3.1.3. Calcilytics increase the pool of PTH by inhibiting the activity of calcium sensing 
receptors [64]. In addition, biological molecules that block sclerostin, a protein secreted 
by osteocyte, would have an anabolic effect on bone because sclerostin has a negative 
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3.1.4. Anti-sclerostin monoclonal antibody has been produced by Amgen Inc (Thousand 
Oaks, CA, USA) with a generic name of romosozumab and trade name of Evenity®.  
Romosozumab improves osteoblast function via the Wnt/catenin signaling pathway 
resulting in increased BMD [83]. The effect, if any, of these relatively new agents 
(romosozumab), on glucose metabolism remains unclear. 
 
3.1.5. Osteocalcin is produced by osteoblasts and can enhance osteoblast differentiation 
through the activation of AMPK. AMPK is a strong antioxidant capable of preventing 
apoptotic degeneration of osteocytes. The ability of the molecule to sensor energy makes 
it a good candidate for the regulation of glucose metabolism [67]. The linking of 
osteocalcin, expressed in osteoblast, to glucose metabolism has created a new concept of 
bone-glucose axis.  Table 3A. 
 
3.2.  Agents that prevent net resorption of bone 
3.2.1. Calcitonin is secreted by the C cells of thyroid gland and prevents bone resorption coupled 
with a reduction in serum and urinary Ca2+ level. However, calcitonin, although approved by the 
FDA is not widely used because of its relatively low efficacy and tendency to cause cancer [68]. 
Studies performed on laboratory animals showed that deletion of calcitonin inhibits 
hyperglycemia in mice [69]. Moreover, another investigation indicated that salmon calcitonin 
increases insulin sensitivity and prevents hyperglycemia when applied orally [84]. In contrast, 
clinical studies involving a relatively few number patients showed that calcitonin induced 
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3.2.2. Estrogens can be used to prevent and treat osteoporosis. However, because of the risk of 
cancer, very low doses have been introduced either alone or in combination with other 
medications used in the treatment of osteoporosis [68]. Reports on the effect of estrogen on the 
risks of developing DM has continued to be controversial but many clinical studies point to 
increased risk of DM in postmenopausal women taking estrogens [70]. Table 3B. 
 
3.2.3. Selective estrogen receptor modulators (SERM) such as tamoxifen and raloxifene have 
been approved for the treatment and prevention of osteoporosis. In spite of improving BMD, its 
major side effect is thromboembolism [86]. Most studies report that the effect of SERM on 
glucose metabolism is neutral [87]. Table 3B. 
 
3.2.4. Bisphosphonates (zoledronic acid, alendronate, risedronate, ibandronate) have been known 
to have anti-osteoporosis effect for last 40 years [71]. They are widely used because of their 
efficacy. Bisphosphonate reduces vertebral and hip fractures by more than 50% [72]. They 
prevent bone resorption by inhibiting osteoclast activity.  Inhibition of osteoclast function is done 
via blocking of farnesyl pyrophosphate synthase [71]. More than 50% reduction in the risk of 
developing T2DM was observed in a large retrospective study involving about 36,000 non-DM 
subjects (aged 60 years and over) taking bisphosphonates for osteoporosis [73]. This observation 
was supported by reports from Yang et al., [74].  
Potentially, anti-resorptive drugs such as alendronate would increase the already normal or 
higher BMD seen in T2DM patients. However, studies have shown that bisphosphonates are 
indeed effective in the reduction of risks to skeletal bone fracture in postmenopausal T2DM 
patients [88]. Although, bisphosphonates may increase BMD, they have been shown to increase 
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outweigh the risk of a putative increase in BMD. Although, bisphosphonates maintain the quality 
of existing BMD, and prevent bone from becoming brittle and fragile, in the short term, in 
contrast long-term (~ 2-3 years) use of bisphosphonates causes bone to become brittle [91]. 
Bisphosphonates have also been reported to cause osteonecrosis of the mandible [68]. It is worth 
noting that strontium ranelate, regarded as a dual agent for bone (facilitates osteoblast function 
and prevent osteoclast-induced bone resorption) has been taken off the market recently in Europe 
because of the risk of myocardial infarction [92]. Table 3B. 
 
3.2.5. Calcium, a component of hydroxyapatite, is crucial for bone health. Insufficient 
calcium intake has been associated with risks of bone fracture [93], however, the benefit 
of calcium supplements still remains controversial. Larger studies appear to confirm the 
beneficial effect of calcium supplement in the reduction associated to bone fracture [93, 
94].  Dietary intake of calcium is preferred to supplements because of the danger of 
complications associated with high serum level of calcium [93]. 
 
3.2.6. Receptor activator of nuclear factor kappa-B ligand (RANKL) is required for the 
maturation, development and differentiation of osteoclasts. Antibody against this molecule will 
therefore block osteoclast activity. Denosumab (RANKL antibody) has therefore been developed 
to treat osteoporosis with an efficacy as high as 68% [75]. Significant insulin sensitivity and 
normalization of blood glucose was observed when RANKL was blocked in both genetic and 
nutritional rodent models of T2DM [76]. In a study of 48 osteoporotic postmenopausal women 
treated with Denosumab, no changes were observed in blood glucose, insulin and insulin 
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3.2.7. Cathepsin K is a cysteine protease used by osteoclasts to degrade the organic components 
of bone matrix, including collagen. Therefore, inhibiting this enzyme will help in the prevention 
of bone resorption by osteoclasts. Phase III clinical trials of odanacatib, a cathepsin K inhibitor, 
show high efficacy in the treatment of osteoporosis. However, the trial and filing for FDA 
approval was terminated in 2016 because of high risk of stroke [78].   
 
3.3. Potential pharmacotherapies for diabetes in patients with osteoporosis 
Biological therapy for the treatment of diabetes-induced osteoporosis would require a double-
pronged approach since the osteoporosis in question develops on the background of DM. This 
means that DM should also be treated and brought under control, using anti-diabetic drugs that 
prevent further deterioration of bone health and osteoporosis in particular.  
Hypoglycemic drugs used in the treatment of diabetes-induced osteoporosis must be able to 
lower blood glucose level and prevent further development of acute and chronic complications of 
DM. These medications should in no way cause any harmful effect on bone metabolism. In fact, 
an ideal drug is one that has both hypoglycemic and bone repairing effects. Drugs or biological 
agents that increase the level of osteocalcin, an osteoblast-derived molecule, could potentially be 
an ideal drug because it stimulates osteoblast proliferation and improves insulin sensitivity [67]. 
 
3.3.1. Alpha glucosidase inhibitors: This group of oral anti-diabetic drugs, which includes, 
acarbose, miglitol and voglibose, prevents the conversion of ingested carbohydrate to 
monosaccharide by competitive inhibition of alpha glucosidase enzymes resident in the brush 
border of enteric cells of the gut [95]. It thus reduces hyperglycemia by preventive absorption of 
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stimulate GLP-1 release from the L-cells of the gut [96].  Either the beneficial or harmful effect 
of alpha glucosidase inhibitors, voglibose, on bone health has not been clearly documented [97]. 
In a large, nationwide study involving more that 2.89 million patients using anti-diabetic drugs, 
no major risks was attributed to patients taking alpha glucosidase inhibitors [98]. The side effects 
of voglibose on bone health have not been documented [99]. Table 4. 
 
 3.3.2. Sulfonylureas (SUs) (e.g. glipizide): A widely used anti-diabetic drug that facilitates 
insulin release from pancreatic beta cells via inhibition of potassium channels [95] has been 
reported to preserve and enhance the structure and function of osteoblast through a variety of 
pathways including the phosphoinositol 3 (PI3) kinase/Akt pathways [100]. The ability of 
sulfonylurea to maintain osteoblast structure and function is probably via insulin, a strong 
anabolic hormone. In contrast, some reports point to increased risk of hip fracture in elderly 
patients taking sulfonylureas [101]. The increase in hip fracture risk observed in elderly patients 
taking SUs may be due to the ability of SUs to cause hypoglycemia, a condition that could 
increase the risk of fall especially in the elderly population. In a recent review of the effect of 
anti-diabetic drugs on the musculoskeletal system, Kalaitzoglou et al [97] reported that the 
current clinical evidence do not support the classification of sulfonylureas (SUs) as been either 
harmful or beneficial to bone architecture. In fact they may be neutral or even beneficial when 
used as monotherapy. Since hypoglycemia is a common side effect of SUs, care should be taken 
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3.3.3. Biguanides (e.g. metformin): Biguanides is an important anti-diabetic drug that inhibits 
hepatic gluconeogenesis, thereby reducing hyperglycemia. It has also been shown to decrease 
hyperlipidemia [95]. The role of metformin on bone structure and function has been a matter of 
controversy [102], but the most recent studies have clearly indicated that metformin may indeed 
have a positive role in bone health because it increases the serum concentration of alkaline 
phosphatase (ALP) and stimulate osteocalcin expression [103]. This indicates that metformin, a 
first-line therapeutic drug for DM, is safe for diabetic patients with osteoporosis. The putative 
beneficial effect of metformin may lie on its ability to reduce hyperglycemia, thereby reducing 
oxidative stress. In spite of the beneficial effect of metformin on bone architecture, some studies 
have indicated that metformin has adverse effect on bone. In a study comprising of 67 adult 
patients with type 2 DM, a significant decrease in spine and hip BMD was observed, one year 
after receiving metformin. The number of patients in this cohort appears to be small and the 
findings contradicts the findings of most reports in the literature on the effect of metformin on 
skeletal bone [104].  Most reports conclude that metformin has no harmful effect on bone 
metabolism [97]. Moreover, it has been shown that metformin stimulates osteocalcin, a hormone 
secreted by osteoblasts, capable of stimulating the proliferation of osteoblasts (an autocrine 
effect) and project a beneficial effect on glucose metabolism [67]. Table 4. 
 
3.3.4. Meglitinides, developed by Novo Nordisk in 1997 acts on ATP-dependent potassium 
channels on pancreatic beta cell membrane to induce insulin release [95]. The effect of 
meglitinides is similar to those of sulfonylureas, albeit with a lesser likelihood of hypoglycemic 
episodes. Little information is available regarding the effect of meglitinides on bone health. 
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developing embryo [105]. Since meglinitides stimulate insulin secretion, the action of this class 
of diabetic drugs would most likely be via insulin as it is for sulfonylureas. In contrast to the 
putative beneficial effects of some meglinitides, increased bone fracture risk was observed when 
repaglinide was used in the treatment of elderly patients aged between 65-74 years, and in 
particular when combined with TZDs [106]. However, no bone fracture was observed when 
repaglinide was used in combination with TZDs for a relatively short duration [107].   
 
3.3.5. Thiazolidinediones  (TZDs) stimulate PPAR-γ to enhance the sensitivity of skeletal muscle 
cells and adipocytes to insulin [108]. Several experimental [109] as well as clinical [110] studies 
have demonstrated that TZDs have adverse effects on bone health because they inhibit 
osteogenesis and stimulate apoptotic destruction of osteocytes. These observations would 
suggest prudence in the use of TZDs for the management of diabetic patients at risk of 
osteoporosis. A recent study involving 2.89 million participants, Choi and co-workers [98] 
observed that patients taking TZDs for DM had a markedly higher risk of bone fracture when 
compared to control. Table 4. 
 
3.3.6.   Glucagon-like peptide (GLP)-1 agonists belongs to the incretin family. GLP-1 increases 
the expression of mol cules (α-1 coll, ALP, Runx2, osteocalcin) involved in bone formation and 
maintenance [111]. Although, there is a lot of controversy on whether GLP-1 agonists can reduce 
the risk of fracture [112], it has recently been shown to significantly reduce the risk of fracture in 
patients with DM [113]. In spite of the beneficial effects on bone metabolism reported in 
laboratory studies, several clinical studies have shown that GLP-1 agonists have no effect on 
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inconsistent with some reporting an ambivalent effect, while others reported an increase in bone 
fracture risk [97]. Table 4. 
 
3.3.7. Dipeptidyl peptidase 4 (DPP-4), an ubiquitous enzyme, located on the plasma membrane 
of osteoblast, osteoclast and osteocyte, has been implicated in the regulation of collagen 
synthesis [114]. The conclusion on the effect of DPP4 inhibitors on osteoporosis has not been 
conclusive.  Some reports have indicated that vildaglitin has no effects whatsoever on bone 
structure and function in osteoporosis after one year of treatment [115]. In contrast, a meta-
analysis of 28 clinical trials showed that DPP-4 inhibitors improve bone health [116]. Since 
DPP-4 inhibitors increase the pool of incretins, which has an anabolic effect of bone, it is 
possible that DPP-4 inhibitors, when used in the right form, dosage and duration, would promote 
bone health in osteoporotic patients. In fact, in a meta-analysis of 28 clinical trials involving a 
cohort of 11,880 patients with more than 9,000 on DPP-4 inhibitors, it was concluded that DPP-4 
inhibitors could be associated with a reduced bone fracture risk [116]. The authors, however, 
agreed that the conclusion has to be treated carefully because of the short duration (~24 weeks) 
of most of the trials. In contrast to some beneficial effect of DPP-4 on bone health, saxaglitpin 
reduced osteoblast number and osteocytic density in metaphyseal trabecular bone of rats [117] 
Overall, many reports showed that the majority of DPP‐4 inhibitors have neutral and/or 
beneficial effects on skeletal bone. However, a large variety of effects were reported for 
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3.3.8.   Sodium glucose co-transporter 2 (SGLT2) inhibitors include canagliflozin, dapagliflozin, 
empagliflozin, and a recently FDA-approved ertugliflozin. Canagliflozin has been shown to 
significantly reduced bone mineral density in diabetic patients. Canagliflozin also increased the 
rate of skeletal fractures [119]. A possible reason for this action is that SGLT2 inhibitors cause 
significant changes in the level of key electrolytes (Mg2+, phosphate, Ca2+, Na+) [120] that 
regulate bone structure and function. In fact, animal studies showed that canagliflozin caused 
increases in the level of biomarkers of bone resorption probably through persistent urinary 
excretion of Ca2+. In contrast, data on the use of empagliflozin in over 4,000 cohort of patients 
did not show increased risk fracture [121]. Since SGLT2 inhibitors increase the risk of 
cardiovascular disease, peripheral arterial disease and lower limb amputation [97], which are also 
common complications of DM [28], extreme care should be taken in the prescription of SGLT2 
inhibitors to diabetes-induced osteoporosis patient. Table 4. 
 
3.3.9. Insulin, an anabolic hormone, stimulates skeletal bone formation, and prevents 
bone loss leading to increased BMD [122] in experimental animals. However, several 
clinical studies have shown that a long-term (~ 5 years) use of insulin significantly 
contribute to BMD loss in type 2 diabetic women aged approximately 56 years [123] and 
increases bone fracture risk [124]. A possible reason for the high risk of bone fracture in 
elderly patients using insulin therapy may be due to the fact that insulin can cause 
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Table 4: Effect of anti-diabetic drugs in osteoporosis 
Anti-diabetic drug Effect on bone/osteoporosis Safe? Reference
1. Alpha glucosidase 
inhibitors   (acarbose, 
miglitol and voglibose) 
Effect on osteoporosis largely 
unknown. However, its hypoglycemic 
and incretin stimulatory effects would 
suggest a beneficial role in the 
treatment of osteoporosis  
Most likely 95-98 
2. Sulfonylureas (e.g. 
glipizide) 
Preserve and maintain osteoblast 
structure and function. May increase 
bone fracture risk because of increased 
sulfonylurea-induced hypoglycemia 
Not likely 95, 97, 
100-101 
3. Biguanides (e.g. 
metformin) 
Sustain bone structure via increases in 
osteocalcin and ALP levels  
Yes 95, 97, 
102-103 
4. Meglitinides (e.g. 
repaglinide, nateglinide 
mitiglinide). 
Repaglinide does not impair bone 
formation in embryo 
Most likely 95, 104-
105 
5.  Thiazolidinediones (e.g. 
pioglitazone, 
rosiglitazone) 
Inhibit osteogenesis; increase blood 
sclerostin; cause osteocyte apoptosis  
No 98, 106-
110 
6. GLP-1 receptor 
agonists 
Increases tissue levels of α-1 collagen, 
ALP, Runx2, osteocalcin 
Yes 97, 111-
113 




effect; others are 
harmful 
114-118 
8. SGLT2 inhibitors Urinary Ca2+ excretion is increased; 
Canagliflozin increases fracture risk; 
empagliflozin does not influence 
fracture risk 
Not  119-121 
9. Insulin Controversial  No 122-124 
 
 
4.    Conclusion 
The prevalence of diabetes mellitus (DM) continues to climb to new heights because of several 
factors including inappropriate diet, and sedentary lifestyle coupled with physical inactivity and 
genetic predisposition. Osteoporosis is a major and common complication of DM that will 
continue to increases in prevalence as the number of DM patients and people with impaired 
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taking a toll on the quality of life of the patient, especially when it is associated with DM. 
Chronic hyperglycemia, oxidative stress and advanced glycated end products have all been 
implicated in the etiopathogenesis of DM-induced osteoporosis. 
In addition to physical exercise, sunshine, and diet rich in protein, vegetable and calcium, several 
anabolic and anti-resorptive osteoporosis drugs have been explored with different degrees of 
success. Since factors (chronic hyperglycemia, oxidative stress) associated with DM are equally 
detrimental to bone structure and function, it is important to treat the hyperglycemia of DM. 
The quality of life of diabetes-induced osteoporotic patient would greatly improve, if all of these 
non-therapeutic approaches are considered and hypoglycaemia-inducing anti-diabetic drugs 
[SGLT2 inhibitors (canagliflozin), insulin, sulfonylureas, repaglinide] are avoided or greatly 
reduced. 
 
 Expert Opinion  
5.1. Approach to the treatment of DM-induced osteoporosis 
DM-induced osteoporosis develops if blood glucose level is not well controlled either because of 
poor medication or non-compliance. Medication is not the only factor needed for the 
maintenance of euglycemia and good bone health. Appropriate physical exercise and vegetable- 
and fruit-rich diet, and smoking cessation are crucial to maintaining overall good health whether 
in DM patient or someone suffering from osteoporosis. The ideal drug or drug combination 
capable of achieving 80-90% efficacy with little or no side effects is still elusive.  
A possible reason for this dilemma is the fact that the prevalence of DM and osteoporosis 
increases with ageing. The advances in medicine and technology observed in the last 4-5 decades 
have significantly increased life span. These advances in medicine and technology increases life 
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DM and osteoporosis are complex, multifactorial metabolic diseases that are influenced by a 
myriad of factors (genetic predisposition, endogenous antioxidant pool, environmental pollutants 
etc.). It is well known that tissue turnover, as seen in wound healing, is slower in patients with 
DM, because of micro- and macroangiopathy, neuropathy, oxidative stress and deformation of 
body proteins by DM-induced glycation. All of these attest to the complexity of managing DM-
induced osteoporosis. 
Anti-osteoporosis drugs that can be safely used in a patient with DM include vitamin D, 
osteocalcin (experimental), bisphosphonates (maximum of 1- 2-year treatment), and RANKL 
antibody. Many other drugs have a neutral or adverse effect on glucose metabolism. Anti-DM 
drugs that can safely be used in patients with osteoporosis include GLP-1 agonists, and 
metformin. Other anti-DM drugs such as insulin, thiazolidinediones, SGLT2 inhibitors, DPP4 
inhibitors and sulfonylureas should be used with caution (Tables 3, 4) because of the risk of 
hypoglycemia, which will in turn increase the prospect of fall and bone fracture risk.  
Osteocalcin-stimulating agents, or perhaps osteocalcin itself and AGE inhibitors are potential 
medications for patients with DM-induced osteoporosis.  
 
5.2. Emerging treatment options for DM-induced osteoporosis 
The use of the anabolic agent, PTH in the treatment of osteoporosis has yielded remarkable 
results. The search for a better PTH analogue capable of stimulating osteoblast at low dose with 
higher efficacy may increase the pool of drugs available for the treatment of diabetes-induced 
osteoporosis. Examples of these endeavors point to the investigation on ostabolin-C and PTH-
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that could stimulate osteoblast activity without adverse effect on glucose metabolism could be 
useful.  
The production of antibodies (e.g. RANKL antibody-Denosumab®, anti-sclerostin antibody- 
Romosozumab®) against specific molecules regulation key pathways in osteoblast and 
osteoclast function is a good way forward.  
Any biological agent that can stimulate osteocalcin, a bone hormone capable of stimulating 
insulin sensitivity and proliferation of osteoblast could be an ideal drug for the treatment of DM-
induced osteoporosis. Medications, such as metformin, capable of stimulating the release of 
osteocalcin or AMPK are useful in the treatment of DM-induced osteoporosis. 
Prevention and/or treatment of AGE-induced glycation of proteins associated with the 
maintenance of bone health is a potential way of managing diabetes-induced osteoporosis since 
AGEs play important role in the pathogenesis of DM and osteoporosis, independent of each 
other. It has been shown that carnosine (β-alanine and L-histidine dipeptide) prevents non-
enzymatic glycation of free amine group and reducing sugar, a process leading to the formation 
of AGEs [125]. Carnosine, a naturally occurring, dipeptide antioxidant is also capable of 
scavenging reactive oxygen species [126] and neutralizing harmful transitional metallic ions in 
the cell [127]. Carnosine and other naturally occurring antioxidants (e.g. glutathione) could be 
potential, non-toxic agents in the prevention and treatment of DM, osteoporosis and a 
combination of both conditions. Drugs targeting the enzyme glyoxalase could also be useful in 
the prevention and treatment of AGEs-induced changes [140] leading to the development of DM 
and osteoporosis because glyoxalase can break down methylglyoxal, the main precursor of 
AGEs. A potential question that researchers could raise with this approach is that these 













Information Classification: General 
that osteoporosis and DM are chronic, multifactorial metabolic disease that should be targeted by 
molecules responsible for a multiple set of complications. A proposed approach to the 
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